Researchers at The University of Texas MD Anderson Cancer Center have discovered that triple negative breast cancer (TNBC) cells can develop resistance to frontline, or neoadjuvant, chemotherapy not by acquiring permanent adaptations, but rather transiently turning on molecular pathways that protect the cells.
Vaginal dryness and painful intercourse are some of the more common adverse events of post-breast cancer treatment therapies and often lead to sexual dissatisfaction and an overall lower quality of life (QOL). However, a new study finds that partnered women may fare better than those without a partner. Study results are published online today in Menopause, the journal of The North American Menopause Society (NAMS).
A team led by Senthil Muthuswamy, PhD, at the Cancer Center at Beth Israel Deaconess Medical Center, has discovered an unexpected relationship between levels of the amino acid leucine (found in beef, chicken, pork and fish and other foods) and the development of tamoxifen resistance in ER+ breast cancer. These findings reveal a potential new strategy for overcoming resistance to endocrine drugs in ER+ breast cancer patients.
Researchers at the University of Zurich and from IBM Research have investigated the vary-ing composition of cancer and immune cells in over one hundred breast tumors. They've found that aggressive tumors are often dominated by a single type of tumor cell. If certain immune cells are present as well, an immune therapy could be successful for a specific group of breast cancer patients.
In recent years, it's become clear that RNA-binding proteins play a major role in cancer growth. These proteins, active in all cells but especially so in cancer cells, bind to RNA molecules and accelerate cancer cell growth. Unfortunately, no cancer treatment has targeted these proteins. Until now.
A Princeton-led team of researchers have discovered a factor that promotes the spread of cancers to bone, opening the way toward treatments that could mitigate cancer's ability to colonize bone. The study by Mark Esposito, Yibin Kang and colleagues appears in the April 15 issue of Nature Cell Biology.
New algorithm successfully identifies patients with a tumor-fueling DNA repair defect found in multiple cancers and treatable with a common cancer drug. Most genetic tests currently used in clinic do not reliably capture the cancer-causing defect, missing many patients who could benefit from treatment.
A UBC medical student has determined that a new surgical guideline is making a difference for breast cancer patients. Alex Monaghan, a second-year Southern Medical Program (SMP) student at UBC Okanagan, recently completed a study using patient data from BC Cancer-Kelowna. His research compared re-operation rates for breast cancer patients before and after a new surgical guideline was introduced five years ago.
UC San Francisco scientists have designed a large-scale screen that efficiently identifies drugs that are potent cancer-killers when combined, but only weakly effective when used alone. The effort, a cross-disciplinary collaboration between UCSF researchers, is described in a study published April 9 in the journal Cell Reports.
Researchers at Mount Sinai have developed a novel approach to cancer immunotherapy, injecting immune stimulants directly into a tumor to teach the immune system to destroy it and other tumor cells throughout the body.